May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Adenovirus–mediated melanoma differentiation associated gene–7 (mda–7) gene therapy for retinoblastoma
Author Affiliations & Notes
  • M. Kataram
    Gene Therapy,
    UAB, Birmingham, AL
  • P. Bhagavatula
    Gene Therapy,
    UAB, Birmingham, AL
  • P.B. Fisher
    Departments of Urology and Pathology, Columbia University,, New York, NY
  • R.V. Gopalakrishna
    Department of Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
  • P. Dent
    Department of Radiation Oncology, Virginia Commonwealth University,, Richmond, VA
  • D.T. Curiel
    Medince Surgery and Pathology, The Gene Therapy Center,
    UAB, Birmingham, AL
  • P.J. Mahasreshti
    Gynecology Oncology, Division of Human Gene Therapy,
    UAB, Birmingham, AL
  • Footnotes
    Commercial Relationships  M. Kataram, None; P. Bhagavatula, None; P.B. Fisher, None; R.V. Gopalakrishna, None; P. Dent, None; D.T. Curiel, None; P.J. Mahasreshti, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 5193. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Kataram, P. Bhagavatula, P.B. Fisher, R.V. Gopalakrishna, P. Dent, D.T. Curiel, P.J. Mahasreshti; Adenovirus–mediated melanoma differentiation associated gene–7 (mda–7) gene therapy for retinoblastoma . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5193.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose:To evaluate the therapeutic potential of "melanoma differentiation–associated gene–7" (mda–7), a novel multifunctional anti–cancer agent, by adenovirus–mediated mda–7 (Ad.mda–7) gene therapy for retinoblastoma. Methods:A replication deficient adenovirus Ad.mda–7 encoding mda–7 was constructed and validated. The human retinoblastoma cells Y79 were injected subcutaneously (1x108 cells/nodule) into CB/17 SCID mice and allowed to form tumors. When the tumors have grown to a size of 50–75mm2, they were treated intratumorally with two doses of either Ad.mda–7 or control virus AdLuc 0.5x1010 particles/nodule or PBS on days 36 and 50 post inoculation of cells, and the tumor size was monitored. Determination of apoptosis in tumors was evaluated by TUNEL assay and angiogensis evaluated by immunohistochemistry. Results:The intratumoral treatment of Ad.mda–7 significantly decreased the tumor size in mice. Whereas the tumors treated with either Adluc or PBS continued to grow. Admda–7 induced significant apoptosis in tumors compared to Adluc. Further, inhibition of angiogenesis in tumors treated with Ad.mda–7 was higher compared to controls Conclusions:Our results suggest that adenovirus mediated mda–7 gene therapy can effectively inhibit retinoblastoma tumor growth. We conclude that the adenovirus–mediated mda–7 gene therapy represents a promising strategy to control retinoblastoma tumor growth.

Keywords: retinoblastoma • adenovirus • gene transfer/gene therapy 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.